Patient Leaflet Updated 24-Oct-2022 | AbbVie Ltd
Zemplar 2 micrograms capsule, soft
Zemplar 1 microgram capsules, soft
Zemplar 2 micrograms capsules, soft
paricalcitol
1. What Zemplar is and what it is used for
2. What you need to know before you take Zemplar
3. How to take Zemplar
4. Possible side effects
5. How to store Zemplar
6. Contents of the pack and other information
Zemplar contains the active substance paricalcitol, which is a synthetic form of active vitamin D.
Active vitamin D is required for the normal functioning of many tissues in the body, including the parathyroid gland and bones. In people who have normal kidney function, this active form of vitamin D is naturally produced by the kidneys, but in kidney failure the production of active vitamin D is markedly reduced. Zemplar therefore provides a source of active vitamin D, when the body cannot produce enough and helps to prevent the consequences of low levels of active vitamin D, namely high levels of parathyroid hormone which can cause bone problems. Zemplar is used in adult patients with kidney disease Stages 3, 4 and 5 and children aged 10 to 16 years with kidney disease Stages 3 and 4.
Your doctor will be able to tell you if these conditions apply to you.
Talk to your doctor or pharmacist before taking Zemplar.
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.
Some medicines may affect the action of this medicine or may increase the likelihood of side-effects. It is particularly important to tell your doctor if you are taking any of the following medicines:
Zemplar may be taken with or without food.
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
There is no adequate data on the use of paricalcitol in pregnant women. Potential risk in human use is not known, therefore paricalcitol should not be used unless clearly necessary.
It is not known if paricalcitol passes into human breast milk. Tell your doctor before breast-feeding while taking Zemplar.
Zemplar should not affect your ability to drive or use machines.
This medicine contains 0.71 mg of alcohol (ethanol) in each 1 microgram capsule and 1.42 mg of alcohol (ethanol) in each 2 micrograms capsule. The amount per capsule of this medicine is equivalent to less than 1 ml beer or wine.
The small amount of alcohol in this medicine will not have any noticeable effects.
Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.
In adult patients the usual initial dose is one capsule every day, or every other day, up to three times a week. Your doctor will use the results of your laboratory tests to decide the correct dose for you. Once Zemplar is started, the dose is likely to need adjusting, depending on how you respond to treatment. Your doctor will help determine the correct dose of Zemplar for you.
In adult patients the usual initial dose is one capsule every other day, up to three times a week. Your doctor will use the results of your laboratory tests to decide the correct dose for you. Once Zemplar is started, the dose is likely to need adjusting, depending on how you respond to treatment. Your doctor will help determine the correct dose of Zemplar for you.
If you have mild to moderate liver disease, your dose will not need to be adjusted. However, there is no experience in patients with severe liver disease.
The usual dose is one capsule every day, or every other day, up to three times a week. Your doctor will use the results of your laboratory tests to decide the correct dose for you. Once Zemplar is started, the dose is likely to need adjusting, depending on how you respond to treatment. Your doctor will help determine the correct dose of Zemplar for you.
In children ages 10 to 16 years of age with chronic kidney disease Stages 3 or 4 the usual initial dose is one capsule every other day, up to three times a week. Your doctor will use the results of your laboratory tests to decide the correct dose for you. Once Zemplar is started, the dose is likely to need adjusting, depending on how you respond to treatment. Your doctor will help determine the correct dose of Zemplar for you.
The efficacy of Zemplar in children with CKD Stage 5 has not been established.
There is no information on the use of Zemplar capsules in children under the age of 10 years.
There is a limited amount of experience of using Zemplar in patients aged 65 years or older. In general no overall differences in effectiveness or safety were seen between patients aged 65 years or older and younger patients.
Too much Zemplar can cause abnormally high levels of calcium in the blood, which can be harmful. Symptoms which can appear soon after taking too much Zemplar may include a feeling of weakness and/or drowsiness, headache, nausea (feeling sick) or vomiting (being sick), a dry mouth, constipation, pains in muscles or bones and a metallic taste in the mouth.
Symptoms which can develop over a longer period of taking too much Zemplar include loss of appetite, drowsiness, weight loss, sore eyes, a runny nose, itchy skin, feeling hot and feverish, loss of sex drive and severe abdominal pain (due to an inflamed pancreas) and kidney stones. Your blood pressure may be affected and heart beat irregularities (palpitations) can occur. The results of blood and urine tests may show high cholesterol, urea, nitrogen and raised levels of liver enzymes. Zemplar may rarely cause mental changes including confusion, drowsiness, insomnia or nervousness.
If you take too much Zemplar, or experience any of the above, seek medical advice immediately.
If you forget to take a dose, take it as soon as you remember. However, if it is almost time for your next dose, do not take the dose that you have missed, simply continue to take Zemplar as previously directed (dose and time) by your doctor.
Do not take a double dose to make up for a forgotten dose.
Unless your doctor tells you to stop your treatment, it is important to keep taking Zemplar as your doctor has directed.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Tell your doctor or nurse if you notice any of the following side effects:
Common (may affect up to 1 in 10 people):
Uncommon (may affect up to 1 in 100 people):
If you experience an allergic reaction, please contact your doctor immediately.
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet.
You can also report side effects (see details below).
By reporting side effects, you can help provide more information on the safety of this medicine.
United Kingdom
or search for MHRA Yellow Card in the Google Play or Apple App Store
Ireland
Keep this medicine out of the sight and reach of children.
This medicinal product does not require any special storage conditions.
Do not use this medicine after the expiry date which is stated on the carton and label after EXP. The expiry date refers to the last day of that month.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.
Zemplar 1 micrograms capsules
Zemplar 2 micrograms capsules
Zemplar 1 micrograms capsules
Zemplar 1 microgram capsules, is an oval, grey soft capsule imprinted with ZA.
Each carton contains either 1 or 4 foil blister packs. Each blister contains 7 capsules.
Zemplar 2 micrograms capsules
Zemplar 2 micrograms capsules, is an oval, orange-brown soft capsule imprinted with ZF.
Each carton contains either 1 or 4 foil blister packs. Each blister contains 7 capsules.
Marketing Authorisation Holder:
UK:
Ireland:
Manufacturer:
Manufacturer:
This medicine is authorised in the Member States of the European Economic Area and in the United Kingdom (Northern Ireland) under the following names:
Czech Republic: Zemplar
Germany: Zemplar 1 Mikrogramm Weichkapseln, Zemplar 2 Mikrogramm Weichkapseln
Greece: Zemplar 1 μικρογραμμάριο καψάκια, μαλακά, Zemplar 2 μικρογραμμάρια καψάκια, μαλακά
Hungary: Zemplar 1 mikrogramm lágy kapszula, Zemplar 2 mikrogramm lágy kapszula
Ireland: Zemplar 1 microgram capsules, soft, Zemplar 2 micrograms capsules, soft
Italy: Zemplar 1 microgrammo capsule molli, Zemplar 2 microgrammi capsule molli
Portugal: Zemplar 1 micrograma cápsulas moles, Zemplar 2 microgramas cápsulas moles
Romania: Zemplar 1 microgram, capsule moi, Zemplar 2 micrograme, capsule moi
Slovakia: Zemplar 1 mikrogram mäkké kapsuly, Zemplar 2 mikrogramy mäkké kapsuly
Slovenia: Zemplar 1 mikrogram mehke kapsule, Zemplar 2 mikrograma mehke kapsule
Spain: Zemplar 1 microgramo cápsulas blandas, Zemplar 2 microgramos cápsulas blandas
United Kingdom (Northern Ireland): Zemplar 1 microgram capsules, soft, Zemplar 2 micrograms capsules, soft
This leaflet was last revised in June 2022.
Other sources of information
For information in large print, tape, CD or Braille, phone 01628 561090 (UK) or 01 428 7900 (Ireland).
AbbVie House, Vanwall Business Park, Vanwall Road, Maidenhead, Berkshire, SL6 4UB, UK
www.abbviemedinfo.com
+44 (0)1628 561 092
+44 (0)1628 561 092
www.abbvie.co.uk